Immune Checkpoint Inhibitors Promising in Melanoma
In two recent studies, researchers found that immune checkpoint inhibitors show promise in treating advanced melanoma.
Personal Melanoma Vaccines Evoke Immune Response
In a first-in-people clinical trial, personalized tailor-made melanoma vaccines given to three patients with advanced melanoma appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors.
Studies Find Interventions Increase HPV Vaccine Coverage
Three recent studies have found that interventions increase the rates of human papillomavirus (HPV) vaccination among teens and young women.
Plasma Exchange Effective in a Subset of Patients with Complex Regional Pain Syndrome
Usually developing following trauma, complex regional pain syndrome (CRPS) has been postulated to be associated with distal degeneration of small-diameter peripheral axons.
Pegylated Recombinant Factor VIII Appears Safe and Efficacious as Prophylactic and On-Demand Hemophilia A Therapy
Baxalta’s BAX 855, a pegylated full-length recombinant factor VIII (rFVIII) based on the licensed rFVIII product Advate, was designed to increase half-life and potentially reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy.
Intravenous Immune Globulin Safe and Effective in Inflammatory Bowel Disease: Retrospective Study
Investigators at Vanderbilt University Medical Center retrospectively extracted data from medical records of IBD patients treated with intravenous immune globulin (IVIG) used to treat these difficult cases.
Influenza Often Overlooked with Bacterial Coinfection
A new study has found that many influenza-positive patients, including those with high-risk conditions, go undiagnosed in favor of a diagnosis of bacterial disease coinfection.
GSK Ebola Shot Is Safe and Provokes an Immune Response
Results from a human trial of GlaxoSmithKline’s Ebola vaccine show it is safe and generates an immune response.
100% Efficacy in Pivotal Trial of Recombinant von Willebrand Factor Used to Treat Severe von Willebrand Disease
The efficacy of Baxter International’s investigational recombinant von Willebrand factor (rVWF) was rated “excellent” (96.9%) or “good” (3.1%) for treatment of 192 bleeding events in 22 patients with severe von Willebrand disease who were enrolled in a Phase 3 clinical trial.
New Method to Alleviate Shortage of Plasma Therapies
Plasma Tech Biopharmaceuticals has developed a new and innovative method to extract plasma proteins from pooled human plasma samples.
